RAD oral presentation at SNO26 on RAD101 Phase IIb data

Sep 13, 2026 at 6:54 PM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Sep 13, 2026 at 6:54 PM EDT

On 6ix: 6ix.com/news/rad-oral-presentation-at-sno26-on-rad101-phase-iib-data

ASX ANNOUNCEMENT September 14, 2026 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging...

View Attachment

6ix hasn’t read this filing yet.

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

Results of MeetingSep 10
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaSep 9
RAD Announces Positive Data from RAD301 P1 Imaging TrialSep 8
Appendix 4E and Preliminary Final ReportAug 28
Change of Director's Interest Notices x 4Aug 27

Later from Radiopharm Theranostics

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual MeetingSep 14
Share purchase plan completedSep 16
Application for quotation of securities - RADSep 16
RADOC New Class Options Range of Units and Top 20 HoldersSep 16
Notification regarding unquoted securities - RADSep 16

All Radiopharm Theranostics news releases

Follow Radiopharm Theranostics into a list and get an email when it puts out news.

Follow Radiopharm Theranostics